Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Randomized Phase III Multi-Institutional Study of TNFerade Biologic With Fluorouracil and Radiotherapy for Locally Advanced Pancreatic Cancer: Final Results

Open access
Herman, Joseph M., Wild, Aaron T., Wang, Hao, Tran, Phuoc T., Chang, Kenneth J., Taylor, Gretchen E., Donehower, Ross C., Pawlik, Timothy M., Ziegler, Mark A., Cai, Hongyan, Savage, Dionne T., Canto, Marcia I., Klapman, Jason, Reid, Tony, Shah, Raj J., Hoffe, Sarah E., Rosemurgy, Alexander, Wolfgang, Christopher L., Laheru, Daniel A.·2013·Journal of Clinical Oncology

Abstract

Purpose: TNFerade biologic is a novel means of delivering tumor necrosis factor alpha to tumor cells by gene transfer. We herein report final results of the largest randomized phase III trial performed to date among patients with locally advanced pancreatic cancer (LAPC) and the first to test gene transfer against this malignancy. Patients and Methods: In all, 304 patients were randomly assigned 2:1 to standard of care plus TNFerade (SOC + TNFerade) versus standard of care alone (SOC). SOC consisted of 50.4 Gy in 28 fractions with concurrent fluorouracil (200 mg/m 2 per day continuous infusion). TNFerade was injected intratumorally before the first fraction of radiotherapy each week at a dose of 4 × 10 11 particle units by using either a percutaneous transabdominal or an endoscopic ultrasound approach. Four weeks after chemoradiotherapy, patients began gemcitabine (1,000 mg/m 2 intravenously) with or without erlotinib (100 to 150 mg per day orally) until progression or toxicity. Results: The analysis included 187 patients randomly assigned to SOC + TNFerade and 90 to SOC by using a modified intention-to-treat approach. Median follow-up was 9.1 months (range, 0.1 to 50.5 months). Median survival was 10.0 months for patients in both the SOC + TNFerade and SOC arms (hazard ratio [HR], 0.90; 95% CI, 0.66 to 1.22; P = .26). Median progression-free survival (PFS) was 6.8 months for SOC + TNFerade versus 7.0 months for SOC (HR, 0.96; 95% CI, 0.69 to 1.32; P = .51). Among patients treated on the SOC + TNFerade arm, multivariate analysis showed that TNFerade injection by an endoscopic ultrasound-guided transgastric/transduodenal approach rather than a percutaneous transabdominal approach was a risk factor for inferior PFS (HR, 2.08; 95% CI, 1.06 to 4.06; P = .032). The patients in the SOC + TNFerade arm experienced more grade 1 to 2 fever and chills than those in the SOC arm (P < .001) but both arms had similar rates of grade 3 to 4 toxicities (all P > .05). Conclusion: SOC + TNFerade is safe but not effective for prolonging survival in patients with LAPC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.44.7516

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 186

Metadata

Authors
Herman, J. M., Wild, A. T., Wang, H., Tran, P. T., Chang, K. J., Taylor, G. E., Donehower, R. C., Pawlik, T. M., Ziegler, M. A., Cai, H., Savage, D. T., Canto, M. I., Klapman, J., Reid, T., Shah, R. J., Hoffe, S. E., Rosemurgy, A., Wolfgang, C. L., & Laheru, D. A.
Venue
Journal of Clinical Oncology
Published
2013-03-01
Volume
31
Issue
7
Pages
886-894
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2130158346
Cited by
186
References
2
FWCI
10.12
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.